Webinar Oligonucleotide Drug Development

Simplifying Oligonucleotide Drug Development Workflows with Mass Spectrometry

This webinar took place on April 24th 2019

Register to download slides & media

Please fill out the form to stream our webinar
Simplifying Oligonucleotide Drug Development Workflows with Mass Spectrometry"

I would like to be contacted by a Bruker sales rep:
I want Bruker to inform me about the latest product news, applications, and events.: *



Bruker is committed to keeping its customers informed and would like to share news of our exclusive events, webinars and product/application updates with you. Please view our updated Privacy and Cookie Policy.


Dear Customer,


thank you for your interest. Your request was successfully submitted.


Best regards,

Your Bruker Team




There has been noteworthy progress in the oligonucleotide therapeutics field over the past 30 years, beginning with antisense oligonucleotides (ASOs) and aptamers and followed about 15 years ago by siRNAs. Recent innovations in the gene editing field is driving the need for oligonucleotides characterization.

MALDI and ESI Mass Spectrometry have prominent roles to play in the life cycle of oligonucleotide drugs from discovery to QC for determination of the molecular weights of natural and synthetic oligonucleotides and in sequencing of DNA and RNA species. Both techniques also have their specific strengths and drawbacks. MALDI-TOF is relatively easy to operate, offers high sensitivity for oligonucleotides, and is well suited to a high-throughput environment. MALDI‐TOF is also reasonably tolerant to the presence of salts, buffers, and other additives. Alternatively, ESI technology maintains high mass accuracy, resolution, and sensitivity over a range of lengths (20–120 bases), but has a reduced throughput and requires more attention to sample cleanliness.

Bruker offers a complete solution for oligonucleotide screening and QC applications with a broad portfolio of innovative and best-in-class MALDI-TOF and UHR ESI-TOF instruments and an integrated software solution for both techniques.

BioPharma Compass 3.1 enables the routine analysis of biopharmaceuticals offering dedicated LC-MS workflows including automated measurements and report generation. Both high resolution ESI-QTOF and MALDI-TOF data can be employed for these analyses. Similarity scores and mass accuracy attributes are the basis for an automatic pass/fail assessment. Reports utilize color coding of results and charts for rapid reviewing. Butterfly plots enable visual dataset comparisons.

Key Learnings

  • Role of Oligonucleotides in drug discovery
  • Oligonucleotide analysis by MALDI and ESI UHR QTOF instruments
  • Biopharma Compass – an integrated software solution for both MALDI and ESI data

Who should attend?

  • Scientists interested in screening and QC of oligonucleotide drugs
  • Scientists interested in MALDI and ESI analysis of oligonucleotides
  • Scientists interested in screening and QC of oligonucleotide drugs
  • Scientists interested in MALDI and ESI analysis of oligonucleotides"               


Anjali Alving, Ph.D.
Anjali Alving, Ph.D.
Senior Applications Scientist, Bruker Daltonics
An analytical scientist by training, Anjali Alving has been working at Bruker Scientific for more than 9 years. She has broad experience with bioanalytical mass spectrometry focusing mainly on Bruker’s ESI UHR QTOFs and Ion trap instruments. In her current capacity as a senior scientist in the Pharma/BioPharma group her work centers on performing  analyses of samples utilizing QTOF and ion mobility mass spectrometry based workflows for oligonucleotide analysis, characterization of intact proteins, peptide mapping, HCP analysis, glycan and polymer analysis. She has also authored technical documents to highlight new and innovative application results using Bruker’s ESI MS systems.